drugset
drugset / Trial / NCT00876798

A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Tolerability of Oral Lixivaptan Capsules in Subjects With Euvolemic Hyponatremia

NCT00876798 ↗

Phase 3 Completed 206 enrolled CardioKine Inc. Biogen · collabCardiokine Biopharma, LLC · collab
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to evaluate the safety and tolerability of oral lixivaptan capsules in subjects with Euvolemic Hyponatremia.

Timeline

Start
2009-06
Primary completion
2010-11
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Lixivaptan Small molecule 25 mg Oral
Subject Lixivaptan Small molecule 50 mg Oral
Subject Lixivaptan Small molecule 100 mg Oral

Indications

No indication recorded.